Total-body irradiation using linac-based volumetric modulated arc therapy: Its clinical accuracy, feasibility and reliability

Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
Bora TasEsat Mahmut Ozsahin

Abstract

To report the feasibility, accuracy, and reliability of volumetric modulated arc therapy (VMAT)-based total-body irradiation (TBI) treatment in patients with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL). From 2015 to 2018, 30 patients with AML or ALL were planned and treated with VMAT-based TBI, which consisted of three isocenters and three overlapping arcs. TBI dose was prescribed to 90% of the planning treatment volume (PTV) receiving 12 Gy in six fractions, at two fractions per day. Mean lung and kidney doses were restricted less than 10 Gy, and maximum lens dose less than 6 Gy. Quality assurance (QA) comprised the verification of the irradiation plans via dose-volume histogram (DVH) based 3D patient QA system. Average mean lung dose was 9.7 ± 0.2 Gy, mean kidney dose 9.6 ± 0.2 Gy, maximum lens dose 4.5 ± 0.4 Gy, mean PTV dose 12.7 ± 0.1 Gy, and heterogeneity index of PTV was 1.16 ± 0.02 in all patients. Grade 3 or more acute radiation toxicity was not observed. When comparing plan and DVH-based 3D patient QA results, average differences of 3.3% ± 1.3 in mean kidney doses, 1.1% ± 0.7 in mean lung doses, and 0.9% ± 0.4 in mean target doses were observed. Linac-based VMAT increased the dose homogeneity of...Continue Reading

References

Nov 1, 1990·International Journal of Radiation Oncology, Biology, Physics·E D Thomas
Mar 1, 1980·International Journal of Radiation Oncology, Biology, Physics·E L Travis
Nov 11, 2005·Medical Physics·Susanta K HuiJames S Welsh
Mar 2, 2006·Australasian Physical & Engineering Sciences in Medicine·T KronT R Mackie
Aug 25, 2009·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·Pascal PommierChristian Carrie
Aug 25, 2009·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·Umberto RicardiFranca Fagioli
Nov 10, 2009·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·Johanna GersteinMichael Bremer
Dec 1, 2009·Medical Dosimetry : Official Journal of the American Association of Medical Dosimetrists·Audrey H ZhuangJeffrey Y C Wong
Oct 12, 2010·Bone Marrow Transplantation·J A PeñagarícanoV Ratanatharathorn
Oct 23, 2010·Medical Physics·Katja M LangenUNKNOWN AAPM Task Group 148
Nov 12, 2010·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·Claudia LinsenmeierSusanne Oertel
May 3, 2011·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·Tobias BöllingNormann Willich
Apr 19, 2015·Radiation Oncology·Henning SalzThomas G Wendt

❮ Previous
Next ❯

Citations

Sep 3, 2020·Journal of Radiation Research·Yuichi AkinoKazuhiko Ogawa
Jan 1, 2020·Radiation Oncology·Christoph LosertStefanie Corradini
Feb 11, 2021·Journal of Applied Clinical Medical Physics·Jose R TeruelDavid L Barbee
Aug 17, 2020·Practical Radiation Oncology·Erik S BlomainSusan M Hiniker
Nov 3, 2020·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Bianca A W HoebenGeert O Janssens
Mar 13, 2021·Practical Radiation Oncology·E SimieleN Kovalchuk
Jan 7, 2021·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·J-P CleuziouJ-Y Giraud
Aug 6, 2021·International Journal of Radiation Oncology, Biology, Physics·Prema RassiahJohn A Kalapurakal
Aug 26, 2021·Journal of Applied Clinical Medical Physics·Madison NaessigNeil Kirby
Apr 30, 2021··A. Rodríguez-LagunaJ. A. Jiménez-Acosta

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.